Grand Pharma Announces Successful Clinical Progress of its Oral 3CL Protease Inhibitor GS221 Against COVID-19
* GS221 has conducted 3 clinical trials. Current results of clinical trials show favorable safety and tolerance in the subjects. After administration, the patients showed trends of improvement of clinical symptoms, shortening time for negative nucleic acid test, and rapid decline of viral load;...
2022-12-30 13:23
3256
GP(HK) Enters into A Few Agreements in the Field of Cancer Diagnostics and Treatment
HONG KONG, Nov. 2, 2020 /PRNewswire/ -- China Grand Pharmaceutical and Healthcare Holdings Limited ("GP (HK)" or the "Company", together with its subsidiaries, the "Group", stock code: 00512) announces that the Group has entered into several agreements with Telix Pharmaceuticals Limited (ASX:TLX)...
2020-11-02 17:01
4425
